Keywords: Bayer, Ciprofloxacin, Cystic fibrosis, FDA, Orphan status

FDA grants orphan status for Bayer’s ciprofloxacin for cystic fibrosis

Article | 12 March 2010

German drug major Bayer HealthCare has received an orphan drug designation from the US Food and Drug Administration for ciprofloxacin ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in